| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 13, 2026 |
| Accession Number: | 0001104659-26-057834 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2021 | $11.00 | Buy | Alliance Global Partners |
6-K - XORTX Therapeutics Inc. (0001729214) (Filer)
6-K - XORTX Therapeutics Inc. (0001729214) (Filer)
6-K - XORTX Therapeutics Inc. (0001729214) (Filer)
CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs. The Company's current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead program for gout. Ongoing evaluation of our
CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange ("TSXV"). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release. This decision was taken following a comprehensive evaluation, the Company determined that maintaining a dual listing on the TSXV does not justify the asso
CALGARY, Alberta , May 19, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has closed its previously announced public offering of 2,659,574 common shares ("Common Shares") or common shares equivalents in lieu thereof ("Pre-Funded Warrants") at a purchase price of US$1.88 (the "Offering"). In connection with the Offering, the Company entered into definitive securities purchase agreements with purchasers to which the Company has issued 183,577 Common Shares and 2,475,997
Alliance Global Partners initiated coverage of XORTX Therapeutics with a rating of Buy and set a new price target of $11.00
CALGARY, Alberta, June 15, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a corporate update and discussion of the strategic path for our gout and other programs. The Company's current focus, following the recent financing and growing investor interest, is solidly aimed at restructuring our corporate and issuer status, re-initiating our drug development programs, and preparing regulatory filings associated with our lead program for gout. Ongoing evaluation of our
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the results of its annual and special meeting of shareholders (the "Meeting") held Tuesday, March 24, 2026. A total of 2,407,148 common shares of the Company were represented at the Meeting, representing approximately 35% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including
CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that further to its press release of October 17, 2025 and an update on December 31, 2025, the Company has entered into an extension agreement with Vectus Biosystems Limited ("Vectus") to allow further time to complete the acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus (the "Acquisition"). The term sheet entered into October 17th (the "Term Sheet") to acquire the novel new chemical
CALGARY, Alberta, Oct. 25, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its earlier press release, the special meeting of shareholders has been rescheduled to 10:00 a.m. (Calgary time) on Friday, October 27, 2023 (the "Meeting"). At the Meeting shareholders will consider a consolidation of the Company's issued and outstanding shares in order for the Company to regain compliance with the continued listing requirements for the NASDAQ Capital Market. About XORTX Therap
CALGARY, Alberta, Nov. 23, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (TSXV:XRTX, NASDAQ:XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announces that it will hold its annual and special meeting of shareholders at 11:00 a.m. (Calgary time) on Monday, December 20, 2021 (the "Meeting"). Materials for the Meeting have been mailed to shareholders and are available on the Company's SEDAR profile and the Company's website. The meeting has been called for shareholders to consider annual matters including the election of directors, re-appointment of Smythe LLP Chartered Accountants as au
SC 13G/A - XORTX Therapeutics Inc. (0001729214) (Subject)
SC 13G - XORTX Therapeutics Inc. (0001729214) (Subject)